New Hydroxychloroquine Study Proves Trump Right, Says It ‘Significantly’ Cuts Death Rate

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on telegram
Telegram

New Hydroxychloroquine Study Proves Trump Right, Says It ‘Significantly’ Cuts Death Rate.

By Benjamin Gill

A substantial study has found that the arthritis medicine hydroxychloroquine sulfate helped patients survive COVID-19. In fact, the study from the Henry Ford Health System in Michigan said the drug “significantly” cut the death rate of patients.

“Treatment with hydroxychloroquine cut the death rate significantly in sick patients hospitalized with COVID-19 – and without heart-related side effects,” the health organization reports.

The randomized double-blind study of 2,500 COVID-19 patients found the drug can be effective if patients received it early in their treatment.

“Our analysis shows that using hydroxychloroquine helped save lives,” said neurosurgeon Dr. Steven Kalkanis, CEO, Henry Ford Medical Group and Senior Vice President and Chief Academic Officer of Henry Ford Health System. “As doctors and scientists, we look to the data for insight. And the data here is clear that there was benefit to using the drug as a treatment for sick, hospitalized patients.”

President Trump had touted the drug early on as a possible experimental treatment for virus patients, but then studies found conflicting results about its effectiveness and the news media hammered him on it. One of the earlier negative studies was later retracted.

Scientists from the Henry Ford Health System believe their study was successful for several reasons.

“The findings have been highly analyzed and peer-reviewed,” said Dr. Marcus Zervos, division head of Infectious Disease for Henry Ford Health System, who co-authored the study with Henry Ford epidemiologist Dr. Samia Arshad. “We attribute our findings that differ from other studies to early treatment, and part of a combination of interventions that were done in supportive care of patients, including careful cardiac monitoring. Our dosing also differed from other studies not showing a benefit of the drug. And other studies are either not peer-reviewed, have limited numbers of patients, different patient populations or other differences from our patients.”

Still, the study showed the drug combination was not able to save everyone, especially patients older than 65 with other health conditions. Roughly 18% of hospitalized patients still died. “Patients who died commonly had serious underlying diseases, including chronic kidney and lung disease, with 88% dying from respiratory failure,” the analysis indicates.

“Currently, the drug should be used only in hospitalized patients with appropriate monitoring, and as part of study protocols, in accordance with all relevant federal regulations,” Dr. Zervos said.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on telegram
Telegram

Never miss any important news. Subscribe to our newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

McIntyre Report

Top 10 Crypto

in USD

in AUD

in GBP

in CAD

Current Price of Bitcoin 2.0

ANR Meme Report

with Nadine Roberts

Episode 002

21st Century Political System

Play Video

Enter email to receive ANR News articles ,2 free ebooks, plus the Global Health Organisation Report

Editor's Pick

Enter email to receive ANR News articles, 2 free e-books, plus the Global Health Organisation Report

Donate Now to Help Take Back Our World

$1000 Donation Turns Into $4000 of the New Global Currency

OWC (Our World Coin) Sponsorship Offer

If you donate to the Resistance you will receive major incentives.

Such as the following in Our World Coin which lists early 2022.

Plus if you donate over $2500 you will also receive 20% in Bitcoin 2.0